Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PLC Systems -- Ignore unavailable to you. Want to Upgrade?

To: ctirry who wrote (586)	3/28/1998 12:04:00 AM
From: nelli	Respond to of 1202

Ditto to Charles who is the voice of reason and experience. There are many many examples of stocks that drop like a rock, albeit slowly, in the days and weeks following FDA panel approval. Buy on the rumor and sell on the news. Don't get stuck holding the bag by being too greedy, guys. Check out recent FDA winners ATIS, CLSR, and even ORG, right after the meeting. (ORG recovers but the other two didn't). There are plenty more examples.

To: ctirry who wrote (586)	4/5/1998 10:11:00 PM
From: Steve H.	Respond to of 1202

Buy on the rumor? Sell on the news? Puleeease. Let's not get ahead of ourselves - it's not a cure for cancer. It's a 'mostly effective' treatment for angina. This stock is too underfollowed to be subject to such "analysis". You either like the story or you don't. If approved, the stock WILL shoot through the roof. If it doesn't get approval, this one-product company will be worthless overnight. There are a lot of fund managers looking for a home run (check the volumes and institutional holdings prior to the last FDA meeting). They're not going to risk getting burned again, so they'll wait to buy large when the approval comes through. It will be a bouncy ride up, but up it will go. FTR, I am long at an average cost of $18. I talked to their sole distributor for China in Beijing last week. (Chindex) The sales force is in place and the supply channels are ready. For medical devices, most countries wait for FDA approval and then give it the green flag in their own country. TMR will be no different. If China is an indicator, one could guess that PLC has similar partners and arrangements in other potentially profitable countries in Europe and Asia as well. Business is good. The lawsuit will against PLC will dry up. The company will be profitable and will be acquired by a major pharmaceutical or medical technology concern. Bibity boboty boo.